新作用机制肺动脉高压靶向治疗药物研究进展

摘要

Pulmonary arterial hypertension (PAH) is a chronic disease that results in narrowing of small pre-capillary pulmonary arteries leading to elevation of pulmonary artery pressure and pulmonary vascular resistance,subsequent right ventricular failure.With the development of pathophysiology and molecular biology of pulmonary hypertension,there are many targeted drugs with novel mechanism under development.In this article,different classes of drugs were reviewed including soluble guanylate cyclase stimulators,mitochondrial modulators,antiinflammatory and immune modulatory therapy,tyrosine kinase inhibitors,5-HT receptor antagonists,right ventricle targeted therapy.%肺动脉高压是一类以肺动脉渐进性闭塞导致肺血管阻力逐渐升高进而发生右心室衰竭的一种恶性肺血管疾病.随着肺动脉高压病理生理学和分子生物学等方面研究的发展,出现了许多新作用机制的肺动脉高压靶向治疗药物.本文根据国内外相关文献报道,本文将从鸟苷酸环化酶激活剂、线粒体调节剂、抗炎和免疫调节剂、酪氨酸激酶抑制剂、5-羟色胺受体拮抗剂、右心室靶向治疗药物等方面进行综述.